Table 1.

Clinical cases who were treated with type I MET-TKI followed by type II MET-TKI

Case	Histology	Driver mutation	Prior type I MET-TKI	Best response	TTF (month)	MET secondary mutation	→	Switched type II MET-TKI	Best response	TTF (month)	MET secondary mutation	References
1	Ad	METex14	crizotinib	SD	15.9	Y1230C	→	merestinib	PR	N/A	N/A	[6]
2	NSCLC	KIF5B-MET	crizotinib	PR	NA	Y1230H	→	cabozanitnib	PR	N/A	N/A	[21]
3	Ad	EGFR mt	savolitinib	CR	9	D1228V	→	cabozantinib	PR	> 5	N/A	[14]
		+	+					+
		MET amp	osimertinib					elrotinib
4	Ad	CD74-ROS1	crizotinib	PR	10	D1228N	→	cabozantinib	PR	3	D1228N	[22]
5	Ad	EGFR mt	savolitinib	PR	18	D1228N	→	cabozantinib	SD	3	D1228N	[20]
		+	+			D1228Y		+			D1228Y
		MET amp	osimertinib			D1228H		osimertinib			D1228H
						Y1230C
6	NSCLC	METex14	crizotinib	PR	NA	D1228N	→	cabozantinib	PD	(-)	N/A	[21]
7	Ad	METex14	crizotinib	PR	8	G1163R	→	glesatinib	PD	(-)	G1163R	[15]
						D1228N					L1195V
						Y1230H					D1228N
						Y1230S
8	Ad	EGFR mt	crizotinib	PR	4	D1228N	→	cabozantinib	PD	(-)	D1228N	[18]
		+	+			D1228H		+
		MET amp	osimertinib			Y1230H		osimertinib
						D1231Y
9	NSCLC	KIF5B-RET	capmatinib	SD	4.5	D1228N	→	cabozantinib	PD	(-)	D1228N	[23]
		+	+					+
		MET amp	selpercatinib					selpercatinib
10	Breast cancer	MET amp	crizotinib	PR	9	D1228N	→	cabozantinib	PD	(-)	N/A	[19]

NSCLC Non-small cell lung cancer, Ad Lung adenocarcinoma, mt mutation, amp amplification, TTF Time to treatment failure, CR Complete response, PR partial response, SD Stable disease, PD Progressive disease, N/A Not available